/CABA

CABA Stock - Cabaletta Bio, Inc.

Q: What is the analyst price target for CABA?

Analyst price target information is not currently available for CABA.

Q: What is CABA's market cap?

Market capitalization information is not currently available for CABA.

Healthcare|Biotechnology|NASDAQ

$2.39-0.83%

$0.02 (-0.83%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+583.3%upside

Target: $16.33

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CABA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.17

52W High$3.67

52W Low$0.99

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-4,813,000	$-1,426,000	$-3,684,000	$-733,000	$-354,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-125,141,000	$-74,660,000	$-54,139,000	$-46,313,000	$-33,833,000
Net Income	$-115,864,000	$-67,675,000	$-52,975,000	$-46,289,000	$-33,339,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-2.34	$-1.65	$-1.81	$-1.80	$-1.44

Company Overview

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

78%

Hold / Neutral

22%

Sell / Underperform

Analyst Consensus🟢 Bullish

7 Bullish2 Neutral/Bearish

Price Targets

$21

Average Target

↑ 792.6% Upside

Now

Low

$21

Average

$40

High

Based on 12 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 10th 2025	Jefferies	Resumed	Buy	$14
December 20th 2024	Evercore ISI	Downgrade	In-line	$6← $15
December 19th 2024	Wells Fargo	Downgrade	Equal Weight	$6← $12
October 10th 2024	UBS	Initiation	Buy	$10
February 5th 2024	Jefferies	Initiation	Buy	$36
November 29th 2023	William Blair	Initiation	Outperform	$38
October 24th 2023	Cantor Fitzgerald	Initiation	Overweight	$40
October 19th 2023	Stifel	Initiation	Buy	$31
September 5th 2023	Citigroup	Initiation	Buy	$22
July 18th 2023	Guggenheim	Initiation	Buy	$34
January 27th 2023	Morgan Stanley	Upgrade	Overweight	$16← $3
August 30th 2022	Morgan Stanley	Downgrade	Equal Weight	$3← $15

Earnings History & Surprises

CABA

Beat Rate

58%

Last 19 quarters

Avg Surprise

+6.6%

EPS vs Estimate

Beats / Misses

11/7

1 met exactly

Latest EPS

$-0.44

Q4 2025

EPS Surprise History

Q1 24

-17.9%

$-0.46vs$-0.39

Q2 24

-6.3%

$-0.51vs$-0.48

Q3 24

-1.8%

$-0.56vs$-0.55

Q4 24

-5.1%

$-0.62vs$-0.59

Q1 25

0.0%

$-0.65vs$-0.65

Q2 25

-6.0%

$-0.71vs$-0.67

Q3 25

-2.8%

$-0.73vs$-0.71

Q4 25

+10.2%

$-0.44vs$-0.49

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 30, 2026	$-0.44	—	—	—
Q4 2025	Nov 10, 2025	$-0.49	$-0.44	+10.2%	✓ BEAT
Q3 2025	Aug 7, 2025	$-0.71	$-0.73	-2.8%	✗ MISS
Q2 2025	May 15, 2025	$-0.67	$-0.71	-6.0%	✗ MISS
Q1 2025	Mar 31, 2025	$-0.65	$-0.65	0.0%	= MET
Q4 2024	Nov 14, 2024	$-0.59	$-0.62	-5.1%	✗ MISS
Q3 2024	Aug 8, 2024	$-0.55	$-0.56	-1.8%	✗ MISS
Q2 2024	May 15, 2024	$-0.48	$-0.51	-6.3%	✗ MISS
Q1 2024	Mar 21, 2024	$-0.39	$-0.46	-17.9%	✗ MISS
Q4 2023	Nov 9, 2023	$-0.39	$-0.37	+5.1%	✓ BEAT
Q3 2023	Aug 10, 2023	$-0.47	$-0.37	+21.3%	✓ BEAT
Q2 2023	May 11, 2023	$-0.48	$-0.45	+6.2%	✓ BEAT
Q1 2023	Mar 16, 2023	$-0.47	$-0.52	-10.6%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.49	$-0.39	+20.4%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.52	$-0.45	+13.5%	✓ BEAT
Q2 2022	May 12, 2022	$-0.64	$-0.45	+29.7%	✓ BEAT
Q1 2022	Mar 17, 2022	$-0.68	$-0.49	+27.9%	✓ BEAT
Q4 2021	Nov 1, 2021	$-0.52	$-0.45	+13.5%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.51	$-0.45	+11.8%	✓ BEAT
Q2 2021	May 3, 2021	$-0.49	$-0.41	+16.3%	✓ BEAT